Carcinomas - Pipeline Review, H1 2013

Description: Carcinomas – Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinomas. Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Carcinomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Carcinomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Carcinomas Overview
Therapeutics Development
An Overview of Pipeline Products for Carcinomas
Carcinomas Therapeutics under Development by Companies
Carcinomas Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Carcinomas Therapeutics - Products under Development by Companies
Carcinomas Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Carcinomas Therapeutics Development
Sequella, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Takara Holdings Inc.
Aduro BioTech
Bayer AG
Momenta Pharmaceuticals, Inc.
PCI Biotech AS
Nanobiotix
Cancer Research Technology Limited
Spectrum Pharmaceuticals, Inc.
Telormedix SA
Cellceutix Corporation
Viventia Biotechnologies Inc.
Lytix Biopharma AS
Carcinomas – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cixutumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ridaforolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(amphinex + bleomycin sulfate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M-402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-1620 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oportuzumab monatox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keventr - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HF-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPI-1342 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOC31-PE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LTX-315 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nelfinavir mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GV-1001 + LTX-315 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lambrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cidofovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-94-9343 - Drug Profile
List of Tables
Number of Products Under Development for Carcinomas, H1 2013
Products under Development for Carcinomas – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Sequella, Inc., H1 2013
Eli Lilly and Company, H1 2013
Merck & Co., Inc., H1 2013
Takara Holdings Inc., H1 2013
Aduro BioTech, H1 2013
Bayer AG, H1 2013
Momenta Pharmaceuticals, Inc., H1 2013
PCI Biotech AS, H1 2013
Nanobiotix, H1 2013
Cancer Research Technology Limited, H1 2013
Spectrum Pharmaceuticals, Inc., H1 2013
Telormedix SA, H1 2013
Cellceutix Corporation, H1 2013
Viventia Biotechnologies Inc., H1 2013
Lytix Biopharma AS, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Carcinomas Therapeutics – Drug Profile Updates
Carcinomas Therapeutics – Discontinued Products
Carcinomas Therapeutics – Dormant Products
Carcinomas Therapeutics – Dormant Products (Contd..1)
Carcinomas Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Carcinomas, H1 2013
Products under Development for Carcinomas – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2574309/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Carcinomas - Pipeline Review, H1 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2574309/">http://www.researchandmarkets.com/reports/2574309/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2LPZB</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
</tr>
</tbody>
</table>

USD 2000
USD 4000
USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World